Concerns Over Rising Aggressive Cancers

Ha- have you seen an increase in aggressive cancers, higher grade cancers, cancers affecting younger people? What is sometimes called turbo cancer? I- and is that a term you like?

I have seen this, um, honestly, and, and I first, uh, saw this phenomenon in 2022. Mm. Um, that was when I

first realized there, there's something else going on, um, since the start of the pandemic that, um, hadn't been properly characterized or looked at. I saw it among my colleagues, uh, physician colleagues, uh, who were coming down... young colleagues who

were coming down with these extremely aggressive cancers- ... uh, and cancers that behaved unlike anything I had seen ... uh, and cancers that behaved unlike anything I had seen before, and

I have seen that since. I've seen that, I've seen that in nursing, I've seen that among teachers, um, you know, these, these various professions

that fa- faced mandates at some point. And I'd seen this phenomenon, these very aggressive cancers, and they would kill the p- person very quickly. You know, they would, they would kill a person in a matter of six months.

Um, and so the behavior, the behavior was very different. I alerted the Canadian Medical Association of this in September of 2022. I had alerted them that, uh, I had, I had

seen a number of my physicians, colleagues, come down with these extremely aggressive cancers. Uh, a- and the term turbo cancer started to be used

around that time as well. It's not a term I like. I don't like the term turbo cancer. It's not a medical term, and, and it's a, it's a term that y- you know, someone who's sort of not aware of this phenomenon, of these aggressive cancers,

uh, may not take seriously. You know, it, it's a term- Mm ... that, that doesn't sound professional. Mm. But it's a term that I think really appropriately describes

what I believe is, is a brand-new phenomenon in cancer- Mm ... uh, which is that some people are now developing extremely aggressive cancers that present at stage four usually.

We're not catching them early on, we're catching them quite late. Stage three, stage four presentations. Young people, uh, these are shocking. When, when you see young women in their 20s present with stage four breast cancer, and

they have no family history, and they have no genetic markers that you can detect, no BRCA one or two mutation- Mm ... uh, that's when you realize

that something is really wrong here. Mm. Uh, colon cancers presenting in young people in their 20s and 30s, we shouldn't be seeing that. Uh, you know,

I always refer to the case of cholangiocarcinomas. These are bile duct cancers that, where the average age was 70. Uh, the average age of presentation. This is, this is a,

uh, this is a cancer of the elderly, and yet we have 20, 25-year-olds presenting with stage four cholangiocarcinoma, something that I'd never seen in, in my career.

A- a- so there is something new happening. Uh, the term turbo cancer has stuck. Uh, I believe it appropriately describes the, the very aggressive nature of these cancers. They grow very

rapidly. They metastasize and spread. Uh, so even when surgeons are trying to go in and get the primary tumor out, by the time they rescan the patient after the surgery, they realize it has already spread, uh, to multiple organs, and they didn't catch it in time.

That, that's how quickly this, this thing moves. And one, one, one particular feature of it which I think is very shocking but very characteristic is these cancers are resistant to conventional chemotherapy, conventional radiotherapy, and even

conventional immunotherapy. And so you see this, this very shocking resistance to chemotherapy. Um, and so you will get either no response or partial

response. Uh, the oncologists really struggle with these cancers, these turbo cancers. Mm. They struggle with them because they throw everything at it, you know.

Mm. The oncologists are genuinely trying to get these- ... cancers under control as, as they used to in the past. ... cancers under control as, as they used to in the past. And so imagine, y- you know, you would have a breast cancer patient who

could live another five years, 10 years, with conventional treatment, and then that patient dies six months later, and you're left wondering, "What is going on? Why are these patients dying so soon after diagnosis?

Why are, why are they resistant to conventional treatment?" Mm. And that's just not being looked at. It's not being studied. It's really being

ignored by, by mainstream oncology. And so Professor Daglish, for example, talks about this. Um- Yes ... you know, he has noticed this phenomenon in the last

few years as well. And the pathologists, you know, I'm really proud of my pathology colleagues like, like Dr. Ryan Cole- Mm

... uh, Dr., Professor Burkhardt in, in Germany- ... uh, who, who've really been, you know, raising the alarm about this, telling ... uh, who, who've really been, you know, raising the alarm about this, telling us there is something wrong here, th- these turbo cancers are real, and they are claiming thousands of young lives, and no one is

studying it. No one is looking into it.